let's be realistic..., page-38

Supertramp,
I agree that Enoxaparin could take a hit from cheaper Fonda.
The blowout in the price differential from the intro of the generic Enox could account for slowing growth seen recently in the Fonda market.

Now that the prices are back into the 'Fonda cost saving' range I am betting on higher overall Fonda use; with ACL/DrR having the lions share of the market.

Also I assume; as the prices of both drugs fall, the relative cost of adverse events to drug cost increases; and this is where Fonda is superior.

JIMO